soquelitinib Search Results


soquelitinib  (MedChemExpress)
94
MedChemExpress soquelitinib
Pharmacological inhibition of Itk with <t>Soquelitinib</t> reduces baseline CD69 expression without impairing CAR T cell activation. (A) Simplified schematic representation of CAR T cell signalling with inhibitors and their targets noted. (B-D) Western blot analysis of PLCγ1 Y783 , Lck Y394 , and Erk1 T202Y204 /Erk2 T185Y187 , respectively, in samples treated with PP1, Soquelitinib, or U0126. One sample is shown here for display. Three replicates and quantification are shown in Supporting Figure 8 . (E-F) Dotplot showing the effect of PP1, Soquelitinib, and U0126 on the percentage of CD69+ WT Jurkats in non co-culture and co-culture samples, respectively. (G-H) As in E and F, except for ζ-CAR Jurkats. (I-J) As in E and F, except for 28ζ-CAR Jurkats. (K-L) As in E and F, except for BBζ-CAR Jurkats. (M-N) As in E and F, except for 28BBζ-CAR Jurkats. Three biological replicates are shown for each flow cytometry experiment.
Soquelitinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/soquelitinib/product/MedChemExpress
Average 94 stars, based on 1 article reviews
soquelitinib - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
soquelitinib stock  (research diets inc)
90
research diets inc soquelitinib stock
Pharmacological inhibition of Itk with <t>Soquelitinib</t> reduces baseline CD69 expression without impairing CAR T cell activation. (A) Simplified schematic representation of CAR T cell signalling with inhibitors and their targets noted. (B-D) Western blot analysis of PLCγ1 Y783 , Lck Y394 , and Erk1 T202Y204 /Erk2 T185Y187 , respectively, in samples treated with PP1, Soquelitinib, or U0126. One sample is shown here for display. Three replicates and quantification are shown in Supporting Figure 8 . (E-F) Dotplot showing the effect of PP1, Soquelitinib, and U0126 on the percentage of CD69+ WT Jurkats in non co-culture and co-culture samples, respectively. (G-H) As in E and F, except for ζ-CAR Jurkats. (I-J) As in E and F, except for 28ζ-CAR Jurkats. (K-L) As in E and F, except for BBζ-CAR Jurkats. (M-N) As in E and F, except for 28BBζ-CAR Jurkats. Three biological replicates are shown for each flow cytometry experiment.
Soquelitinib Stock, supplied by research diets inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/soquelitinib stock/product/research diets inc
Average 90 stars, based on 1 article reviews
soquelitinib stock - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Pharmacological inhibition of Itk with Soquelitinib reduces baseline CD69 expression without impairing CAR T cell activation. (A) Simplified schematic representation of CAR T cell signalling with inhibitors and their targets noted. (B-D) Western blot analysis of PLCγ1 Y783 , Lck Y394 , and Erk1 T202Y204 /Erk2 T185Y187 , respectively, in samples treated with PP1, Soquelitinib, or U0126. One sample is shown here for display. Three replicates and quantification are shown in Supporting Figure 8 . (E-F) Dotplot showing the effect of PP1, Soquelitinib, and U0126 on the percentage of CD69+ WT Jurkats in non co-culture and co-culture samples, respectively. (G-H) As in E and F, except for ζ-CAR Jurkats. (I-J) As in E and F, except for 28ζ-CAR Jurkats. (K-L) As in E and F, except for BBζ-CAR Jurkats. (M-N) As in E and F, except for 28BBζ-CAR Jurkats. Three biological replicates are shown for each flow cytometry experiment.

Journal: Cellular signalling

Article Title: Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling

doi: 10.1016/j.cellsig.2025.112204

Figure Lengend Snippet: Pharmacological inhibition of Itk with Soquelitinib reduces baseline CD69 expression without impairing CAR T cell activation. (A) Simplified schematic representation of CAR T cell signalling with inhibitors and their targets noted. (B-D) Western blot analysis of PLCγ1 Y783 , Lck Y394 , and Erk1 T202Y204 /Erk2 T185Y187 , respectively, in samples treated with PP1, Soquelitinib, or U0126. One sample is shown here for display. Three replicates and quantification are shown in Supporting Figure 8 . (E-F) Dotplot showing the effect of PP1, Soquelitinib, and U0126 on the percentage of CD69+ WT Jurkats in non co-culture and co-culture samples, respectively. (G-H) As in E and F, except for ζ-CAR Jurkats. (I-J) As in E and F, except for 28ζ-CAR Jurkats. (K-L) As in E and F, except for BBζ-CAR Jurkats. (M-N) As in E and F, except for 28BBζ-CAR Jurkats. Three biological replicates are shown for each flow cytometry experiment.

Article Snippet: For inhibitor treatment experiments, Jurkats were collected, washed once in plain RPMI 1640, then resuspended in the inhibitor solutions - 0.2% DMSO, 5 μM PP1 (MedChemExpress #HY-13804-5mg), 2 μM Soquelitinib (MedChemExpress #HY-150298), 5 μM U0126 (Cell Signaling Technologies #9903), 4 μM TPI-1 (MedChemExpress #HY-100463-5mg), 2 μM PTPN22-IN-1 (MedChemExpress #HY-139693-5mg), 10 μM pervanadate - at a concentration of 3×10 7 cells/mL for 3 hours at 37 C, 5% CO 2 in a humidified incubator.

Techniques: Inhibition, Expressing, Activation Assay, Western Blot, Co-Culture Assay, Flow Cytometry